SCHEMBL23908251

SCHEMBL23908251

N#Cc1ccc(C(=O)NC2(c3ccc(Br)cc3)CCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.47
CTSB P07858 2/20 0.47
CTSS P25774 2/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CXCR3 P49682 1/20 0.42
POLB P06746 2/20 0.42
HDAC1 Q13547 2/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPK1 P28482 1/20 0.40
GPR183 P32249 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439087 0.83 NPC1 (0.39) CTSLCTSBCTSSNPC1RAB9A
SCHEMBL22439020 0.82 HDAC1 (0.48) CTSLCTSBCTSSNPC1POLB
SCHEMBL22438841 0.82 CTSL (0.41) CTSLCTSBCTSSNPC1RAB9A
SCHEMBL22439042 0.79 CA1 (0.41) CTSLCTSBCTSSNPC1RAB9A
SCHEMBL22439054 0.79 DEGS1 (0.46) CTSLCTSBCTSSNPC1RAB9A
SCHEMBL1608427 0.79 VNN1 (0.42) NPC1RAB9ACXCR3POLBGAA
SCHEMBL23908262 0.78 EGLN1 (0.50) CXCR3
SCHEMBL22439074 0.77 CXCR3 (0.43) CTSLCTSBCTSSCXCR3POLB
SCHEMBL22439083 0.77 DEGS1 (0.43) NPC1RAB9ACXCR3ALDH1A1LMNA
SCHEMBL22438959 0.76 WDR91 (0.57) CXCR3HDAC1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3709986-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2022-11-15 US disclosed
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317091-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU CTSL 3464/4885CTSB 1813/4885CTSS 2337/4885
US-11498904-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, INMT CTSL 3605/4885CTSB 1549/4885CTSS 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.